Vanguard amends 13G for 10X Genomics (NASDAQ: TXG) reporting 0 shares
Filing Impact
Filing Sentiment
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary
10X Genomics Inc ownership filing: The Vanguard Group filed an amendment to a Schedule 13G reporting 0 shares beneficially owned of Common Stock, representing 0% of the class. The filing states Vanguard and related managed accounts have rights to dividends or sale proceeds but hold no >5% interest.
Positive
- None.
Negative
- None.
FAQ
What does Vanguard's Schedule 13G/A for TXG state about ownership?
Vanguard reports holding 0 shares, representing 0% of the class. The amendment clarifies that Vanguard and managed accounts have dividend or proceeds rights in general but currently do not exceed a 5% beneficial ownership threshold.
Is Vanguard acting on behalf of other investors in this Schedule 13G/A?
The filing notes Vanguard manages investment companies and accounts that may have rights to dividends or sale proceeds. It also states no other person's interest reported exceeds 5% for the securities disclosed in this amendment.
What is the legal significance of a Schedule 13G/A amendment by a large manager?
An amendment updates a passive investor’s disclosed position; it is informational rather than an operational action. Here the amendment reports a nil beneficial ownership position and reaffirms custodial/managerial relationships with underlying accounts.
Who signed the Schedule 13G/A for Vanguard and when was it signed?
The filing is signed by Ashley Grim, Head of Global Fund Administration. The signature block shows the date 03/24/2026, attesting to the amendment's contents on that date.